Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges

Kinan Alhallak; Jennifer Sun; Amanda Jeske; Chaelee Park; Jessica Yavner; Hannah Bash; Berit Lubben; Ola Adebayo; Ayah Khaskiah; Abdel Kareem Azab

doi:10.3390/cancers13122853

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges

Cancers (Basel). 2021 Jun 8;13(12):2853. doi: 10.3390/cancers13122853.

Authors

Kinan Alhallak^{1

2}, Jennifer Sun^{1

2}, Amanda Jeske^{1

2}, Chaelee Park¹, Jessica Yavner¹, Hannah Bash¹, Berit Lubben¹, Ola Adebayo¹, Ayah Khaskiah³, Abdel Kareem Azab^{1

2}

Affiliations

¹ Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
² Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
³ Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit 627, West Bank, Palestine.

Abstract

MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.

Keywords: bispecific T cell engagers; chimeric antigen receptor-T cells; multiple myeloma.

Publication types

Review